RAC 2.20% $1.78 race oncology ltd

[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-104

  1. 139 Posts.
    lightbulb Created with Sketch. 33
    I have seen no adverse news in the clinicals since I have been a holder and am comfortable that under the CEO they are executing the strategy. I wish you well with your investment in IMU.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.